Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Future Directions in Soft Tissue Sarcoma

October 21st 2015

Phase III Data on Eribulin in Advanced STS

October 21st 2015

Early Data With Olaratumab in Soft Tissue Sarcoma

October 21st 2015

Patient Selection in Soft Tissue Sarcoma

October 21st 2015

Use of Trabectedin in Soft Tissue Sarcoma

October 21st 2015

Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

October 21st 2015

Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

October 21st 2015

Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

October 21st 2015

Importance of Surgery and Radiation in Advanced STS

October 21st 2015

Integrating Community Oncologists Into the Multidisciplinary Team

October 21st 2015

Key Members of the Multidisciplinary Team

October 21st 2015

Implementation of Multidisciplinary Sarcoma Care

October 21st 2015

Multidisciplinary Assessment of Soft Tissue Sarcomas

October 21st 2015

Accurately Diagnosing Soft Tissue Sarcoma

October 21st 2015

Incidence and Subtypes of Advanced Soft Tissue Sarcoma

October 21st 2015

Treating Bone and Soft Tissue Sarcomas

October 16th 2015

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.

Demetri Interprets Survival Outcomes for Trabectedin in Soft Tissue Sarcomas

October 8th 2015

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

FDA Grants Priority Review to Eribulin for Soft Tissue Sarcoma

September 30th 2015

The FDA has granted a priority review designation to eribulin mesylate as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Trabectedin OS Data Unclear in Phase III Sarcoma Study

September 26th 2015

The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.

Trabectedin Effective in Heavily Pretreated Metastatic Soft Tissue Sarcomas

September 16th 2015

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.